July 25, 2025 | FlipTheLoss Desk
U.S. stock futures edged slightly higher on Friday as investors absorbed a wave of fresh quarterly earnings ahead of next week’s Federal Reserve policy meeting. While the overall market remained steady, several big-name companies saw major swings in premarket trading.
Here’s a quick look at the top premarket stock movers on July 25, 2025 and the earnings stories behind them.
Intel (NASDAQ: INTC) Slumps 8% on Job Cuts and Weak Outlook
Intelstock plunged over 8% in premarket trading after the semiconductor
giant announced steeper-than-expected losses for the third quarter. The company
also confirmed a massive workforce
reduction, targeting a headcount of 75,000 by the end of 2025, down 22% from the end of
2024.
The cuts will be done through attrition and “other means,” raising
concerns about operational impact. Intel continues to battle intense
competition from AMD and Nvidia while investing heavily in its foundry
business.
Investor Takeaway: Short-term pain could bring long-term gains if restructuring pays off, but risk remains high.
Centene (NYSE: CNC) Tumbles 13% on Surprise Loss
Health insurance provider Centene stock fell sharply by 13% after
posting a surprise quarterly loss. The company blamed higher medical costs tied to its insurance offerings for
the earnings miss.
This drop comes despite expectations of steady
growth in Medicaid and marketplace enrollments. Rising healthcare utilization
seems to be eating into margins.
Investor Takeaway: Monitor trends in healthcare cost inflation before considering a rebound entry.
Deckers Outdoor (NYSE: DECK) Soars 12% on Sales Beat
Footwear and apparel company Deckers saw its stock jump 12%, thanks
to strong Q1 results. The
company reported better-than-expected performance from its Hoka running shoes and Ugg boots.
Revenue and earnings blew past Wall Street
expectations, highlighting strong brand momentum despite cautious consumer
spending.
Investor Takeaway: Deckers continues to shine as a premium brand, with strong e-commerce growth supporting upside.
Phillips 66 (NYSE: PSX) Up 0.6% on Refining Margins
Phillips
66 gained 0.6% after beating Q2 profit expectations, helped by higher refining margins and lower turnaround
costs. The energy major also reported solid operational performance in
its chemicals and marketing units.
Investor Takeaway: Strong oil and gas fundamentals remain supportive, but be wary of volatility in crude prices.
Charter Communications (NASDAQ: CHTR) Slides 7.6% on Weak Earnings
Charter
stock dropped nearly 8% after reporting disappointing second-quarter results. The cable giant
continues to lose subscribers amid rising competition from streaming services.
The company also missed expectations on both
revenue and profit, signaling further challenges ahead in the broadband and
pay-TV space.
Investor Takeaway: The shift to streaming remains a headwind. Recovery could take time unless broadband gains pick up.
Newmont (NYSE: NEM) Gains 1.9% on Gold Prices
Newmont
shares rose 1.9% after the world’s
largest gold miner posted stronger-than-expected earnings for Q2.
Performance was buoyed by higher gold
prices and strong mine
operations.
Investor Takeaway: Newmont offers inflation hedge exposure. Gold’s recent strength makes this a watchlist stock.
Paramount Global (NASDAQ: PARA) Up 1.1% on FCC Approval
Media company Paramount rose 1.1% in premarket trade after the Federal Communications Commission (FCC)
approved its $8 billion merger with
Skydance Media. This move could reshape the U.S. entertainment
landscape.
Investor Takeaway: Merger optimism may drive momentum, but long-term value depends on execution.
Boyd Gaming (NYSE: BYD) Up 0.8% on Strong Q2
Boyd
Gaming stock climbed 0.8% after posting solid second-quarter numbers. The casino operator
benefited from strong customer loyalty
and improving trends in retail play.
Investor Takeaway: Las Vegas names still attract interest, but macro factors like inflation could limit upside.
Sarepta (NASDAQ: SRPT) Slides 10%
on Regulatory Setback
Sarepta
Therapeutics plunged 10% after European regulators rejected approval for Elevidys, its gene
therapy for Duchenne muscular dystrophy. The rejection was a blow to investor
expectations on global rollout.
Investor Takeaway: Regulatory hurdles add risk to Sarepta’s drug pipeline. Recovery may depend on U.S. results and new trials.
Should You Buy Intel (INTC) at $2,000 Investment Level?
Intel’s current dip has sparked curiosity
among value investors. At current valuations, some experts believe INTC could offer upside if restructuring
and cost cuts translate into future profitability.
According to InvestingPro’s AI tools, several undervalued stocks, including Intel, showed 30%+ gains post-correction in past cycles. Still, investors should weigh the risks tied to tech layoffs and market share battles.
Investment Advisory: Read Before You
Invest
Stock markets are subject to volatility and unpredictability,
especially around earnings season and Fed meetings. Always do your own research and consult with a SEBI-registered financial advisor before
investing.
Investments in individual stocks carry the risk of capital loss. Past performance is not indicative of future returns.
For more financial updates and smart investing insights, visit:
👉 Fliptheloss.in
